May 22nd 2024
February 14th 2024
From an interview conducted during Patient-Centered Oncology Care 2023.
August 17th 2023
February 23rd 2023
Payer Concerns With Including Novel Immunotherapies on Clinical Pathways
Combination Immunotherapies in Melanoma
Understanding Immunotherapy Efficacy and Safety
Clinical Pathway Consideration and Payer Decisions
Safety and Efficacy of Targeted Therapy Versus Immunotherapy in Melanoma
Clinician Concerns with Adopting Clinical Pathways
Health Plan Perspectives on Clinical Pathways
Clinical Pathways Should Keep Pace With New Data
Distinguishing Between Companion and Complementary Diagnostic Tests
Health Plan Coverage of Diagnostic Tests for PD-L1 Expression
Predictive Biomarker Testing for Immunotherapy in Melanoma
How Important Are Biomarkers for Treatment Selection in Lung Cancer?
Early Biomarkers and Coverage Decisions in Immuno-Oncology
Immunotherapy in Oncology and the Role of the PD-L1 Biomarker
Clinical Insights on Newer Immunotherapies in Lung Cancer
Existing Treatment Landscape of Immunotherapies
Considerations for Designing "Value Calculators" for Oncology Therapies
Segment 14: The Future of Clinical Pathways
Segment 13: Place for Palliative Care in Clinical Pathways
Segment 12: Patient Awareness About Clinical Pathways
Segment 11: Can Clinical Pathways Restrict Patient Access?
Segment 10: Can Clinical Pathways Be Personalized?
Segment 9: Ease of Integrating Pathways Based on Site of Care
Segment 8: Pathways as a Means to Deliver High-Value Care
Segment 7: How Flexible Are Oncology Care Pathways?
Segment 6: Standardizing Clinical Pathways Across Health Plans
Segment 5: Clinical Pathways - A Shared Decision-Making Tool?
Segment 4: How Rigorous Should Pathway Development Be?
Segment 3: Considerations for Developing a Clinical Pathway
Segment 2: What Are Oncology Care Pathways?